Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Bullboard Posts
Post by wanttoretireearlyon Mar 04, 2017 5:58pm
263 Views
Post# 25932545

University of Chicago says...Cleveland Clinic says...Hospita

University of Chicago says...Cleveland Clinic says...HospitaAs a sane person I will take a  word from the University of Chicago, Clevelend Clinic and Hospitla for Sick Kids over a few paid or unpaid bashers and pumpers on this board.
University of Chicago says “I expect that an assessment of RV volume and function using the VMS™ will become part of the routine clinical ultrasound evaluation for patients at risk for PAH."
A simple way to detect and monitor PAH is gravely needed and this methodology will be extremely useful to quantify interventions (therapeutic and surgical) performed on the right ventricle,” stated Roberto M. Lang, MD, is an internationally renowned cardiologist and specialist in echocardiography and Past President of the American Society of Echocardiography.
 Clevelend Clinic says “The VMS™ will enable us to better image the hearts of patients at risk for pulmonary hypertension and is a wonderful alternative to MRI."
Hospital for Sick Kids says “We found an excellent agreement between both techniques and, based on these findings, decided to introduce the method in our Echocardiography Laboratory.
The first results of a clinical trial to evaluate feasibility, reproducibility and accuracy of the system are really impressive and demonstrate that the VMS is a robust clinical tool. I see a multitude of potential applications for the VMS that can significantly impact the care of patients with heart disease,” said Luc Mertens MD, Head, Echocardiography Cardiology."
source: https://www.ventripoint.com/
Bullboard Posts